Fanconi anemia (FA) is an autosomal recessive disease manifesting regressive bone marrow failure, skeletal abnormalities, altered skin pigmentation, developmental defects, decreased fertility, chromosome instability and increased risk of acute myelogenous leukemia. Therefore FA presents bone marrow stem cell failure with risk of leukemia. It couples genome instability with clonal tumor development. This Program Project will use a multidisciplinary approach to understanding the molecular defects in FA and developing therapy for the disease. Clinical disciplines represented by the investigators include medicine, pediatrics, medical genetics, hematology and oncology. Scientific areas include molecular hematology, molecular genetics, mouse genetics, gene therapy, stem cell biology and DNA repair. The proposed Program will have three investigative units and three support core components: Project 1 will investigate functions of the FANC proteins as mechanisms for genome stability and tumor suppression. The work will test whether the FA pathway is directly involved in genome stability via chromatin remodeling and whether FANCD2 interacts in a complex with DNA processing proteins from other pathways. Project 2 will develop novel practical and useful therapies for FA. The work will utilize new methods of gene therapy based on site-specific recombination and develop rational small molecule therapy for pre-clinical testing. Existing mouse models of FA are key tools for this work. Project 3 will determine the function of FANC proteins in signaling in stem cells as a means to understanding the anemia of FA and the failure of STAT signal transduction in FA cells. Work will also address the loss of apoptotic cues for these cells in clonal development of leukemia. The Cytogeneties Core will serve a critical role since analysis of chromosome breakage will be the end point for many of the proposed studies. The Cell Repository Core will characterize FA cells lines as to complementation group and provide investigators with isogenic FA lines, corrected and uncorrected, for comparative trials in the above projects. The Administrative Core will be responsible for organization of all meetings and financial management.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL048546-13
Application #
7274297
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
13
Fiscal Year
2006
Total Cost
$98,221
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Whiteaker, Jeffrey R; Zhao, Lei; Ivey, Richard G et al. (2018) Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage. DNA Repair (Amst) 65:47-53
Kroeger Jr, Paul T; Drummond, Bridgette E; Miceli, Rachel et al. (2017) The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development. Dev Biol 428:148-163
Rondinelli, Beatrice; Gogola, Ewa; YĆ¼cel, Hatice et al. (2017) EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 19:1371-1378
Karras, Georgios I; Yi, Song; Sahni, Nidhi et al. (2017) HSP90 Shapes the Consequences of Human Genetic Variation. Cell 168:856-866.e12
Mouw, Kent W; Goldberg, Michael S; Konstantinopoulos, Panagiotis A et al. (2017) DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 7:675-693
Garbati, Michael R; Hays, Laura E; Rathbun, R Keaney et al. (2016) Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages. J Leukoc Biol 99:455-65
Zhang, Qing-Shuo; Tang, Weiliang; Deater, Matthew et al. (2016) Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood 128:2774-2784
Zhang, Haojian; Kozono, David E; O'Connor, Kevin W et al. (2016) TGF-? Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell 18:668-81
Zhang, Qing-Shuo; Benedetti, Eric; Deater, Matthew et al. (2015) Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling. Stem Cell Reports 4:90-102
Lombardi, Anne J; Hoskins, Elizabeth E; Foglesong, Grant D et al. (2015) Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res 21:1962-72

Showing the most recent 10 out of 106 publications